--(www.USEquityNews.com)-- 06/19/2008 - Healthcare industry alert provided by U.S. Equity News. Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced recently that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at the Jefferies Second Annual Healthcare Conference in New York on Thursday, June 26, 2008, at 1:00 p.m. EDT. A live audio webcast of the presentation may be accessed through the Investors page of the Company's website at www.Osiris.com. An audio replay of the webcast will be available for 30 days following the conference.
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth, recently issued the following statement on the outcome of recently's meeting of the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmologic Drug Advisory Committee (DODAC) regarding the expanded use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis. The Committee recommended, with an 8-5 vote, to approve ENBREL for the treatment of moderate to severe plaque psoriasis in children. The DODAC panel also provided input to the FDA regarding use in patients with more severe plaque psoriasis.
The International Regulome Consortium (IRC) announced recently it has signed a non-binding letter of intent with Invitrogen Corporation (NASDAQ: IVGN) to develop tools for stem cell research that will aid in the development of new therapies for some of the world's most debilitating diseases. The agreement was signed here yesterday at the annual meeting of the Biotechnology Industry Organization. Invitrogen will contribute services and technology to help IRC researchers in their goal of mapping the genetic circuit board that regulates how stem cells give rise to specialized cells such as neurons. IRC is a third generation genome project, involving 58 researchers from 34 institutions in 12 countries.
TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma. The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition. For more information, please visit www.stocksjournal.com.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
